Review of the risks and benefits of yellow fever vaccination including some new analyses

Expert Review of Vaccines

Volumn 11, Issue 4, 2012, Pages 427-448

  Monath, Thomas P ^a  

^a Kleiner Perkins Caufield & Byers   (United States)

Author keywords

vaccine; viscerotropic adverse events; yellow fever

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN OAS1; PROTEIN OAS2; PROTEIN OAS3; RANTES; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; ASEPTIC MENINGITIS; ASTHENIA; AUTOIMMUNE DISEASE; BACKACHE; BREAST FEEDING; CHILL; DRUG CONTRAINDICATION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; ENCEPHALOMYELITIS; GENETIC PREDISPOSITION; GUILLAIN BARRE SYNDROME; HEPATITIS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMIGRANT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INNATE IMMUNITY; LEUKOCYTE COUNT; MALAISE; MENINGOENCEPHALITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; MYALGIA; NEUROTROPISM; NEUTROPENIA; NONHUMAN; POSTMARKETING SURVEILLANCE; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; RISK FACTOR; SEROCONVERSION; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS ABORTION; STILLBIRTH; THYMUS DISEASE; VACCINATION; VIREMIA; VISUAL IMPAIRMENT; WHITE DOT SYNDROME; YELLOW FEVER;

AFRICA; HUMANS; RISK ASSESSMENT; SOUTH AMERICA; SURVIVAL ANALYSIS; TRAVEL; VACCINATION; VACCINES, ATTENUATED; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84860577315     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.6     Document Type: Review

References (136)

1. Monath TP, Gershman M, Staples EJ, Barrett ADT. Yellow fever vaccine. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, NY, USA (2012) (In Press).
2. Barrett ADT, Monath TP. Epidemiology and ecology of yellow fever. Adv. Virus Dis. 61, 291-315 (2003).
3. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741-747 (2009).
4. Barrett AD, Teuwen DE. Yellow fever vaccine- how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol. 21(3), 308-313 (2009).
5. Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Expert Rev. Vaccines 7(5), 579-587 (2008). (Pubitemid 351881342)
6. Domingo C, Neidrig M. Safety of 17D derived yellow fever vaccines. Exp. Opin. Drug Saf. 8(2), 211-221 (2009).
7. Monath TP. Treatment of yellow fever. Antiviral Res. 78(1), 116-124 (2008). (Pubitemid 351381173)
8. Sawyer WA, Kitchen SF, Lloyd W. Vaccination against yellow fever with immune serum and virus fixed for mice. J. Exp. Med. 55(6), 945-969 (1932).
9. Monath TP. Yellow fever vaccines. In: History of Vaccine Development. Plotkin SA (Ed.). Springer, NY, USA, 109-136 (2011).
10. Frierson JG. The yellow fever vaccine: a history. Yale J. Biol. Med. 83(2), 77-85 (2010).
11. Theiler M, Smith HH. Use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65(6), 787-800 (1937).
12. Mass vaccination against yellow fever in Brazil 1937-54. In: Yellow Fever Vaccination. Smithburn KC, Durieux C, Koerber R et al. (Eds). WHO, Geneva, Switzerland, 123-140 (1956).
13. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 56(2), 159-167 (1998) (Pubitemid 28419278)
14. Silva ML, Martins MA, Espirito-Santo LR et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 29(3), 583-592 (2011).
15. Monath TP, Nichols R, Archambault WT et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a III multicenter, double-blind clinical trial. Am. J. Trop. Med. Hyg. 66(5) 533-541 (2002).
16. Camacho LA, de Aguiar SG, Freire M da S et al. Reactogenicity of yellow fever vaccines in a randomized, placebocontrolled trial. Rev. Saude. Publica. 39(3), 413-420 (2005). (Pubitemid 41200551)
17. Monath TP, Cetron MS, McCarthy K et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum. Vaccin. 1(5), 207-214 (2005).
18. Philipps J, Schonfeld C, Schleehauf DM et al. Side effects of travel vaccinations. Data collection via telephone survey in Berlin. Wien. Klin. Wochenschr. 108(19), 615-620 (1996). (Pubitemid 26348075)
19. Durbin AP, Setse R, Omer SB et al. Monitoring adverse events following yellow fever vaccination using an integrated telephone and internet-based system. Vaccine 27(44), 6143-6147 (2009).
20. Levenbook IS, Pelleu LJ, Elisberg BL. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J. Biol. Stand. 15(4), 305-313 (1987). (Pubitemid 18046861)
21. Stuart G. Reactions following vaccination against yellow fever. In: Yellow Fever Vaccination. Smithburn KC, Durieux C, Koerber R et al. (Eds). WHO Monograph Serial No. 30, WHO, Geneva, Switzerland, 143-189 (1956).
22. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine 17(22), 2908-2917 (1999). (Pubitemid 29323019)
23. Mar ID, Niang I, Guicheney A et al. Encephalitis following anti-yellow fever vaccination (from 248 cases observed at Dakar in 1965). Ann. Pediatr. (Paris) 14(3), 181-191 (1967).
24. Martin M, Weld LH, Tsai TF et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerging Infect. Dis. 7(6), 945-951 (2001). (Pubitemid 33115772)
25. Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23(25), 3256-3263 (2005). (Pubitemid 40523118)
26. Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077-6082 (2008).
27. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun. Dis. Intell. 28(2), 244-248 (2004); Erratum in: Commun. Dis. Intell. 28(3), 348-352 (2004).
28. Martins R de M, S Maia M de L, dos Santos EM et al. Yellow fever vaccine postmarketing surveillance in Brazil. Procedia. Vaccinol. 2, 178-183 (2010).
29. Guimard T, Minjolle S, Polard E et al. Short report: incidence of yellow fever vaccine-associated neurotropic disease. Am. J. Trop. Med. Hyg. 81(6), 1141-1143 (2009).
30. Farez MM, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch. Neurol. 68(10), 1267-1271 (2011).
31. Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116-125 (2009).
32. Gaucher D, Therrien R, Kettaf N et al. Yellow fever induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2009).
33. Roukens AH, Soonawala D, Joosten SA et al. Delayed antibody response to yellow fever vaccination in elderly coincides with prolonged viremia. Presented at: 12th International Conference on Travel Medicine. Boston, MA, USA, 8-12 May 2011.
34. Minor PD. Neurovirulence tests of three 17D yellow fever vaccine strains. Biologicals 39(3), 167-170 (2011).
35. Jennings AD, Gibson CA, Miller BR et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169(3), 512-518 (1994).
36. Nickells M, Chambers TJ. Neuroadapted yellow fever virus 17D determinants in the envelope protein govern neuroinvasiveness for SCID mice. J. Virol. 77(22), 12232-12242 (2003). (Pubitemid 37339876)
37. Mandl CW, Allison SL, Holtzmann H et al. Attenuation of tick-borne encephalitis by structure-based sitespecific mutagenesis of a putative flavivirus receptor binding site. J. Virol. 74(20), 9601-9609 (2000).
38. Monath TP. Recombinant, chimeric, live, attenuated vaccines against flaviviruses and alphaviruses. In: Replicating Vaccines - A New Generation. Rappuoli R, Dormitzer P, Mandl C (Eds). Burkhäuser Verlag, Basel, Switzerland, 349-438 (2010).
39. Macnamara FN. Reactions following neurotropic YF vaccine given by scarification in Nigeria. Trans. R. Soc. Trop. Hyg. 47, 199-208 (1953).
40. Martin M, Tsai TF, Cropp CB et al. Multisystemic illness in elderly recipientsof yellow fever vaccine report of four cases. Lancet 358(9276), 98-104 (2001). (Pubitemid 32709847)
41. Vasconcelos PF, Luna EJ, Galler R et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358(9276), 91-97 (2001). (Pubitemid 32709846)
42. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358(9276), 121-122 (2001). (Pubitemid 32709852)
43. Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans. R. Soc. Trop. Med. Hyg. 101(10), 967-971 (2007). (Pubitemid 47317251)
44. Belsher JL, Gay P, Brinton M et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25(50), 8480-8485 (2007). (Pubitemid 350137593)
45. Nasidi A, Monath TP, DeCock K et al. Urban yellow fever epidemic in western Nigeria, 1987. Trans. R. Soc. Trop. Med. Hyg. 83(3), 401-406 (1989). (Pubitemid 19163236)
46. Pulendran B, Miller J, Querec TD et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198(4), 500-507 (2008).
47. Querec TD, Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated yellow fever vaccine 17D. Adv. Exp. Med. Biol. 590, 43-53 (2007).
48. Barwick R; Eidex for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet 364(9438), 936 (2004). (Pubitemid 39208454)
49. Whittembury A, Ramirez G, Hernández H et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27(43), 5974-5981 (2009).
50. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai. 85(1), 131-134 (2002).
51. Bae H-G, Domingo C, Tenorio A et al. Immune responses during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect. Dis. 197(11), 1577-1584 (2008). (Pubitemid 351706488)
52. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Positional cloning of the murine flavivirus resistance gene. Proc. Natl Acad. Sci. USA 99(14), 9322-9327 (2002). (Pubitemid 34764612)
53. Elbahesh H, Jha BK, Silverman RH, Scherbik SV, Brinton MA. The Flvr-encoded murine oligoadenylate synthetase 1b (Oas1b) suppresses 2-5A synthesis in intact cells. Virology 409(2), 262-270 (2010).
54. Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD. A mouse model for studying viscerotropic disease caused by yellow fever infection. PLoS Pathog. 5(10), e1000614 (2009).
55. Lim JK, Lisco A, McDermott DH et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 5(2), e1000321 (2009).
56. Barkhash AV, Perelygin AA, Babenko VN et al. Variability in the 2-5-Oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. J. Infect. Dis. 202(12), 1813-1818 (2010).
57. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202(8), 1087-1098 (2005). (Pubitemid 41464502)
58. Glass WG, McDermott DH, Lim JK et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203(1), 35-40 (2006). (Pubitemid 43139642)
59. Monath TP. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am. J. Trop. Med. Hyg. 82(5), 919-921 (2010).
60. Seligman SJ. Yellow fever virus vaccine - associated deaths in young women. Emerg. Infect. Dis. 17(10), 1891-1893 (2011).
61. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29(28), 4544-4555 (2011).
62. Fitzner J, Coulibaly D, Kouadio DE et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 23(2), 156-162 (2004). (Pubitemid 39505084)
63. Alexander LN, Seward JF, Santibanez TA et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292(14), 1696-1701 (2004). (Pubitemid 39346671)
64. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: national surveillance in the United States. N. Engl. J. Med. 281(22), 1201-1208 (1969).
65. Balraj V, Miller E. Complications of mumps vaccines. Rev. Med. Virol. 5, 219-227 (1995). (Pubitemid 26094487)
66. Monath TP, Cetron MS. Prevention of yellow fever in persons travelling to the tropics. Clin. Infect. Dis. 34(1), 1369-1378 (2002); Erratum in: Clin. Infect. Dis. 35(1), 110 (2002). (Pubitemid 34507947)
67. Lopez-Velez R, Bayas J-M. Spanish travelers to high-risk areas in the tropics: airport survey of travel health knowledge, attitudes, and practices in vaccination and malaria prevention. J. Travel Med. 14(5), 297-305 (2007). (Pubitemid 47460250)
68. Prazuk T, Semaille C, Defayolle M et al. Vaccination status of French and European travelers: a study of 9156 subjects departing Paris to 12 tropical destinations. Rev. Epidemiol. Sante Pub. 46(1), 64-67 (1998). (Pubitemid 28080804)
69. Hamer DH, Connor BA. Travel health knowledge, attitudes and practices among United States travelers. J. Travel Med. 11(1), 23-26 (2004). (Pubitemid 38198771)
70. Namikawa K, Iida T, Ouchi K, Kimura M. Knowledge, attitudes and practices of Japanese travelers on infectious disease risks and immunization uptake. J. Travel Med. 17(3), 171-175 (2010).
71. Jentes ES, Poumerol G, Gershman MD et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk forYellow Fever. Lancet Infect. Dis. 11(8), 622-632 (2011).
72. Moreno ES. Vaccine coverage and adverse reactions to yellow fever vaccine survey in Buri city, São Paulo State, 2009. BEPA Bol Epidemiol Paul. 6(71), 12-24 (2009).
73. Veras MASM, Flannery B, de Moraes JC, Teixeira AM, Luna EJ. Yellow fever vaccination coverage among children in Brazilian capitals. Vaccine 28(39), 6478-6482 (2010).
74. De Oliveira ATR, Ervatti LR, O'Neill MMVC. Migrações internas. O panorama dose deslocamentos populacionals no Brasil: PNADs e censos demográficos. In: Reflexões sobre os Deslocamentos Populacionais no Brasil. Inst Bras Geogr Estatística (IBGE). de Oliveira LAP, de Oliveira ATR (Eds). Rio de Janeiro, Brazil, 28-48 (2011).
75. Anon. Outbreak news, Paraguay. Wkly Epidemiol. Rec. 83(12), 105 (2008).
76. Pinheiro FP, Travassos da Rosa APA, Moraes MAP et al. An epidemic of yellow fever in central Brazil 1972-1973. I. Epidemiological studies. Am. J. Trop. Med. Hyg. 27(1), 125-132 (1978). (Pubitemid 8269680)
77. Izurieta RO, Macaluso M, Watts DM et al. Anamnestic immune response to dengue and decreased severity of yellow fever. J. Global Infect. Dis. 1(2), 111-116 (2009).
78. Chaves TSS Vasconcelos MJ, Filho NO, Alves, JR Yellow Fever in a Brazilian family returning from vacation in an endemic area: relevant clinical features and epidemiological issues. J. Travel Med. 16(6), 433-435 (2010).
79. Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg. 87(3), 337-339 (1993).
80. Monath TP, Craven RB, Adjukiewicz A et al. Yellow fever in the Gambia, 1978-1979: epidemiologic aspects with observations on the occurrence of Orungo virus infections. Am. J. Trop. Med. Hyg. 29(5), 912-920 (1980).
81. Monath TP, Onejeme S, Okweke G et al. Surveillance of yellow fever in Nigeria, 1970-1971. Nigerian Med. J. 21(2), 178-186 (1972).
82. Advisory Committee on Immunization Practices. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 59(RR-7), 1-27 (2010).
83. Bentlin M, Almeida R, Rabello Coelho K et al. Vertical transmission of yellow fever (Brazil, 2009). Emerg. Infect. Dis. 17(9), 1779-1780 (2011).
84. Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J. Infect. Dis. 168(6), 1520-1523 (1993). (Pubitemid 23344916)
85. Nishioka Sde A, Nunes-Araujo FR, Pires WP et al. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop. Med. Int. Health 3(1), 29-33 (1998). (Pubitemid 28081016)
86. Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24(9), 1421-1426 (2006). (Pubitemid 43222053)
87. Cavalcanti DP, Salomã M-A, Lopez- Camelo J, Pessoto MA, The Campinas Group of Yellow Fever Immunization During Pregnancy. Early expopsure to yellow fever vaccine during pregnancy. Trop. Med. Int. Health 12(7), 833-837 (2007).
88. Anon. Possible West Nile virus transmission to an infant through breastfeeding - Michigan, 2002. MMWR Morb. Mortal. Wkly Rep. 51(39), 877-878 (2002).
89. CDC. Transmission of yellow fever vaccine virus through breast-feeding- Brazil, 2009. MMWR Morb. Mortal. Wkly Rep. 59(5), 130-132 (2010).
90. Kuhn S, Twele-Montecinos L, MacDonald J, Webster P, Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183(4), e243-e245 (2011).
91. Findlay GM, MacCallum FO. Transmission of yellow fever virus to monkeys by mouth. J. Path. Bact. 49(1), 53-61 (1939).
92. Niedrig M, Stolte N, Fuchs D et al. Intranasal infection of macaques with yellow fever (YF) vaccine strain 17D: a novel and economical approach for YF vaccination in man. Vaccine 17(9-10), 1206-1210 (1999). (Pubitemid 29132956)
93. Veit O, Hatz C, Niedrig M, Furrer H. Yellow fever vaccination in HIV-infected patients. HIV Therapy 4(1), 17-26 (2010).
94. Goujon C, Tohr M, Feuillie V et al. Good tolerance and efficacy of yellow fever vaccine among subjects carriers of human immunodeficiency virus. Presented at: 4th Intlernational Conference on Travel Medicine. Acapulco, Mexico, 23-27 April 1995.
95. Pistone T, Verdiere CH, Receveur MC et al. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIVinfected patients. Curr. HIV Res. 8(6), 461-466 (2010).
96. Veit O, Neidrig M, Chapuis-Taillard C et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis. 48(5), 659-666 (2009).
97. Sibailly TS, Wiktor SZ, Tsai TF et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus Type 1. Pediatr. Infect. Dis. J. 16(12), 1177-1179 (1997).
98. Domingo C, Yactayo S, Agbenu E et al. Detection of yellow fever 17D genome in urine. J. Clin. Microbiol. 49(2), 760-762 (2011).
99. Van De Winkel K, Van den Daele A, Vasn Gompel A, Van den Ende J. Factors influencing standard pretravel health advice - a study in Belgium. J. Travel. Med. 14(5), 288-296 (2007). (Pubitemid 47460249)
100. Kaplan JE, Nelson, DB, Schonberger LB et al. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull. WHO 62(4), 555-590 (1984).
101. Burn GL, Svensson L, Sanchez-Blanco C et al. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett. 585(23), 3689-3698 (2011).
102. Martinez M, Vilella A, Pumerola T et al. Persistence of yellow fever vaccine RNA in urine. Vaccine 29(18), 3374-3376 (2011).
103. Monath TP, Liu J, Kanesa-Thasan N et al. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci USA 103(17), 6694-6699 (2006).
104. Kuno G. Persistence of arboviruses and antiviral antibodies in vertebrate hosts: its occurrence and impacts. Rev. Med. Virol. 11(3), 165-190 (2001). (Pubitemid 32510201)
105. Murray K, Walker C, Herrrington E et al. Persistent infection with West Nile virus years after initial infection. J. Infect. Dis. 201(1), 2-4 (2010).
106. Wu X, Guzman H, Tesh RB, Xiao SY. Persistent infection and associated nucleotide changes of West Nile virus serially passaged in hamsters. J. Gen. Virol. 89(Pt 12), 3073-3079 (2008).
107. Starling KA, Falletta JM, Fernbach DJ. Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. Exp. Hematol. 3(4), 244-248 (1975).
108. Barban V, Girerd Y, Aguirre M et al. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine 25(15), 2941-2950 (2007). (Pubitemid 46420609)
109. CDC. Transfusion-related transmission of yellow fever vaccine virus - California, 2009. MMWR Morb. Mortal. Wkly Rep. 59(2), 34-37 (2010).
110. Cook GC. Fatal yellow fever contracted at the Hospital for Tropical Diseases, London, UK in 1930. Trans. R. Soc Trop. Med. Hyg. 88(6), 712-713 (1994).
111. Bauer JH, Hudson NP. Passage of virus of yellow fever through skin. Am. J. Trop. Med. Hyg. s1-8, 371-378 (1928).
112. Foy BD, Kobylinkski KC, Chilson Foy JL et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 17(5), 880-882 (2011).
113. Roukens AH, Vossen AC, van Dissel JT, Visser LG. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 27(26), 2408-2409 (2009).
114. Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J. Allergy Clin. Immunol. 103(4), 698-701 (1999). (Pubitemid 29295580)
115. Pande H, Lacy BE, Crowell MD. Inflammatory causes of gastroparesis: report of five cases. Dig. Dis. Sci. 47(12), 2664-2668 (2002). (Pubitemid 35471603)
116. Stangos A, Zaninetti M, Petropoulos I et al. Mutiple evanescent White Dot Syndrome following simultaneous hepatitis-A and yellow fever vaccination. Ocul. Immunol. Inflamm. 14(5), 301-304 (2006). (Pubitemid 44627588)
117. Schmöeller D, Keiserman M, Staub H et al. Yellow fever vaccination and Kawasaki Disease. Pediatr. Infect. Dis. J. 28(11), 1037-1038 (2009).
118. Perumalswami P, Peng L, Odin J. Vaccination as a triggering event for autoimmune hepatitis. Semin. Liver Dis. 29(3), 331-334 (2009).
119. Bayas J-M, Gonzalez-Álvarez R, Guinovart C. Herpes zoster after yellow fever vaccination. J. Travel Med. 14(1), 65-66 (2007) (Pubitemid 46114990)
120. Miric D, Mahious F, Fondop E, Masngin d'Ouince V, Millet C, Hallet-Lezy AM. Yellow fever vaccination and vestibular schwannoma: a dangerous combination. Lancet 58(1), 202-203 (2010).
121. Ferguson M, Shin J, Knezevic I, Minor P, Barrett A. WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow fever Vaccines, Geneva, Switzerland, 13-14 May 2009. Vaccine 28(52), 8236-8245 (2010).
122. Rabello A, Orsini M, Disch J et al. Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine. Rev. Soc. Bras. Med. Trop. 35(2), 177-180 (2002). (Pubitemid 34453444)
123. Panthier R. Às propos de quelques cas de réactions nerveuses tardives observées chez des nourrissons après vaccination antiamarile (17D). Bull. Soc. Pathol. Exot. 49, 477-494 (1956).
124. Fox JP, Penna HA. Behavior of 17D yellow fever virus in rhesus monkeys: relation to substrain, dose and neural or extraneural inoculation. Am. J. Epidemiol. 38(2), 152-172 (1943).
125. Belmusto-Worn VE, Sanchez JL, McCarthy K et al. Randomized, doubleblind, Phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am. J. Trop. Med. Hyg. 72(2), 189-197 (2005). (Pubitemid 41278904)
126. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25(4), 539-544 (1973).
127. Hayes EB. Is it time for a new yellow fever vaccine? Vaccine 28(51), 8073-8076 (2010).
128. Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 29(35), 6008-6016 (2011).
129. Monath TP, Lee CK, Julander JG et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28(22), 3827-3840 (2010).
130. Anderson LA, Gadalla S, Morton LM et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int. J. Cancer 125, 398-405 (2009).
131. Monath TP, Fowler E, Johnson CT et al. A clinical trial of an inactivated, cell culture vaccine against yellow fever. N. Engl. J. Med. 364(14), 1326-1333 (2011).
132. WHO. International Health Regulations, 2005. WHO, Geneva, Switzerland (2007).
133. Thomas PA. The need for organization and collaboration: establishing a thymoma registry. Thorac. Surg. Clin. 21(1), 131-134 (2011).
134. Lim SS, Drenkard C, McCune WJ et al. Population-based lupus registries: advancing our epidemiologic understanding. Arthritis Rheum. 61(10), 1462-1466 (2009).
135. Jacobson DL, Gange SJ, Rose N, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84(3), 223-243 (1997). (Pubitemid 27398022)
136. Betterle C, Morlin L. Autoimmune Addison's disease. Endocr. Dev. 20, 161-172 (2011).